HMBD-001

DRUG3 trials

Sponsors

Cancer Research UK, Hummingbird Bioscience

Conditions

Advanced Cutaneous Squamous Cell CarcinomaAdvanced Esophageal Squamous Cell CarcinomaAdvanced Head and Neck Squamous Cell CarcinomaAdvanced or Metastatic Squamous Non-Small Cell Lung CancerBladder CancerCastration-resistant Prostate CancerCervical CancerCervical Squamous Cell Carcinoma

Phase 1

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Active, not recruitingNCT05057013

Cancer Research UKBladder Cancer, Castration-resistant Prostate Cancer, Cervical Cancer +11

Start: 2021-11-10End: 2025-11-30Target: 81Updated: 2025-08-11

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

RecruitingNCT05910827

Hummingbird BioscienceAdvanced Cutaneous Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma +4

Start: 2024-02-05End: 2027-12-01Target: 398Updated: 2026-05-27

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Active, not recruitingNCT05919537

Hummingbird BioscienceLocally Advanced Solid Tumor, Metastatic Solid Tumor, Non-Small Cell Lung Cancer +1

Start: 2023-09-06End: 2031-03-01Target: 68Updated: 2025-04-18

Related Papers

Abstract 5796: A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations

Cancer Research2024-03-22

Abstract 2659: Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker-selected pre-clinical models of squamous cell carcinomas

Cancer Research2023-04-04